These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 16466988

  • 1. Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.
    Baur M, Fazeny-Doerner B, Hudec M, Sevelda P, Salzer H, Dittrich C.
    Cancer Invest; 2006 Feb; 24(1):22-7. PubMed ID: 16466988
    [Abstract] [Full Text] [Related]

  • 2. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
    Sørensen P, Pfeiffer P, Bertelsen K.
    Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
    [Abstract] [Full Text] [Related]

  • 3. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Jan; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 4. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
    González-Martín A, Crespo C, García-López JL, Pedraza M, Garrido P, Lastra E, Moyano A.
    Gynecol Oncol; 2002 Mar; 84(3):368-73. PubMed ID: 11855871
    [Abstract] [Full Text] [Related]

  • 5. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer.
    Chiara S, Tognoni A, Pastrone I, Tomasello L, Brema F, Di Costanzo G, Folco U, Pronzato P, GONO (Italian Gruppo Oncologico del Nord-Ovest).
    Gynecol Oncol; 2004 May; 93(2):474-8. PubMed ID: 15099965
    [Abstract] [Full Text] [Related]

  • 6. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study.
    Sutton GP, Blessing JA, Homesley HD, Malfetano JH.
    Gynecol Oncol; 1994 Apr; 53(1):24-6. PubMed ID: 8175017
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma.
    Beddoe AM, Dottino PR, Cohen CJ.
    Mt Sinai J Med; 1993 Sep; 60(4):311-6. PubMed ID: 8232377
    [Abstract] [Full Text] [Related]

  • 8. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
    Talbot SM, Rankin C, Taub RN, Balcerzak SP, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH.
    Cancer; 2003 Jul 15; 98(2):331-6. PubMed ID: 12872353
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].
    Zhen ZJ, Sun XF, Xia Y, Wang ZH, Ling JY.
    Ai Zheng; 2006 Dec 15; 25(12):1550-2. PubMed ID: 17166384
    [Abstract] [Full Text] [Related]

  • 10. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
    Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C.
    Gynecol Oncol; 2007 May 15; 105(2):399-403. PubMed ID: 17292457
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Pappo AS, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, Gebhardt M, Pratt C, Grier HE.
    J Clin Oncol; 2005 Jun 20; 23(18):4031-8. PubMed ID: 15767644
    [Abstract] [Full Text] [Related]

  • 12. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
    Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC.
    Gynecol Oncol; 1996 Oct 20; 63(1):25-7. PubMed ID: 8898163
    [Abstract] [Full Text] [Related]

  • 13. Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer.
    Park S, Ahn MJ, Ahn JS, Lee J, Hong YS, Park BB, Lee SC, Hwang IG, Park JO, Lim H, Kang WK, Park K.
    Lung Cancer; 2007 Oct 20; 58(1):116-22. PubMed ID: 17624473
    [Abstract] [Full Text] [Related]

  • 14. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
    Lashkari A, Chow WA, Valdes F, Leong L, Phan V, Twardowski P, Kapoor N, Molina A, Al-Kadhimi Z, Frankel P, Somlo G.
    Anticancer Res; 2009 Aug 20; 29(8):3281-8. PubMed ID: 19661346
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Kim SG, Oh SY, Kwon HC, Lee S, Kim JH, Kim SH, Kim HJ.
    Jpn J Clin Oncol; 2007 Oct 20; 37(10):744-9. PubMed ID: 17923456
    [Abstract] [Full Text] [Related]

  • 16. [Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
    Huang YH, Wen XP, Hu L.
    Ai Zheng; 2002 Aug 20; 21(8):907-9. PubMed ID: 12478905
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT.
    J Clin Oncol; 2008 Dec 10; 26(35):5761-6. PubMed ID: 19001330
    [Abstract] [Full Text] [Related]

  • 18. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P, After 6 Italian Cooperative Group.
    J Clin Oncol; 2009 Oct 01; 27(28):4642-8. PubMed ID: 19704064
    [Abstract] [Full Text] [Related]

  • 19. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
    Dorval T, Soussain C, Beuzeboc P, Garcia-Giralt E, Jouve M, Livartowski A, Mosseri V, Palangié T, Scholl S, Sastre X, Pouillart P.
    J Infus Chemother; 1996 Oct 01; 6(1):47-9. PubMed ID: 8748008
    [Abstract] [Full Text] [Related]

  • 20. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G, North-Eastern German Society of Gynecological Oncology.
    Cancer Chemother Pharmacol; 2009 Aug 01; 64(3):585-91. PubMed ID: 19156414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.